F8632
Fmoc-Ala-OH
Sinónimos:
N-(9-Fluorenylmethoxycarbonyl)-L-alanine, Fmoc-L-alanine
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
Fórmula empírica (notación de Hill):
C18H17NO4
Número CAS:
Peso molecular:
311.33
EC Number:
252-660-6
UNSPSC Code:
12352200
MDL number:
Beilstein/REAXYS Number:
2225975
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarlemp
147-153 °C (lit.)
storage temp.
−20°C
SMILES string
C[C@H](NC(=O)OCC1c2ccccc2-c3ccccc13)C(O)=O
InChI
1S/C18H17NO4/c1-11(17(20)21)19-18(22)23-10-16-14-8-4-2-6-12(14)13-7-3-5-9-15(13)16/h2-9,11,16H,10H2,1H3,(H,19,22)(H,20,21)/t11-/m0/s1
InChI key
QWXZOFZKSQXPDC-NSHDSACASA-N
Clase de almacenamiento
13 - Non Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
K R Sunil Kumar et al.
ACS nano, 8(5), 4157-4165 (2014-04-01)
To apply motor proteins as natural nanomolecular machines to transporting systems in nanotechnology, complete temporal control over ON/OFF switching of the motility is necessary. We have studied the photoresponsive inhibition properties of azobenzene-tethered peptides for regulation of kinesin-microtubule motility. Although
Ngoc-Duc Doan et al.
Journal of peptide science : an official publication of the European Peptide Society, 21(5), 387-391 (2014-11-18)
The solid-phase synthesis of azapeptides possessing a C-terminal aza-residue has been accomplished by a protocol featuring regioselective alkylation of benzhydrylidene-aza-glycinamide and illustrated by the syntheses of [aza-Lys(6)] growth-hormone-releasing peptide-6 analogs.
Soo Min Cho et al.
Scientific reports, 4, 6777-6777 (2014-10-28)
Amyloid-β (Aβ) is one of the few neuropathological biomarkers associated with transporters of the blood-brain barrier (BBB). Despite the well-characterized clinical indication of decreasing Aβ levels in the cerebrospinal fluid (CSF) during the development of Alzheimer's disease (AD), the link